WO2023165381A1 - Composé de statine à base d'acyle ayant une activité inhibitrice de lipase, son procédé de préparation et son utilisation - Google Patents

Composé de statine à base d'acyle ayant une activité inhibitrice de lipase, son procédé de préparation et son utilisation Download PDF

Info

Publication number
WO2023165381A1
WO2023165381A1 PCT/CN2023/077498 CN2023077498W WO2023165381A1 WO 2023165381 A1 WO2023165381 A1 WO 2023165381A1 CN 2023077498 W CN2023077498 W CN 2023077498W WO 2023165381 A1 WO2023165381 A1 WO 2023165381A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
formula
food
solvate
hydrate
Prior art date
Application number
PCT/CN2023/077498
Other languages
English (en)
Chinese (zh)
Inventor
王勇
刘海利
许建林
Original Assignee
上海临贤生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海临贤生物科技有限公司 filed Critical 上海临贤生物科技有限公司
Publication of WO2023165381A1 publication Critical patent/WO2023165381A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention belongs to the field of biomedicine, and more specifically, the invention relates to acyltadine compounds having lipase inhibitory activity and a preparation method thereof, and the role of such lipase inhibitors in preventing and treating obesity, type 2 diabetes and cancer induced by obesity applications in diseases.
  • Body mass index (BMI) greater than 30kg/m 2 or more than 20% of the standard body weight is called obesity. It is a chronic disease of rapid accumulation of body fat due to energy intake exceeding metabolic expenditure. Studies have shown that obesity can damage the organs and systems of the human body, and is a risk factor for various diseases such as type 2 diabetes, hypertension, cardiovascular disease and cancer. In recent years, due to excessive intake of high-calorie substances and lack of physical exercise, the number of overweight people has increased dramatically. According to statistics, in 2019, the number of obese people in China exceeded 250 million, ranking first in the world. Diseases caused by obesity consume a large amount of medical expenses, making it a public health problem that has to be ignored. Therefore, it is of great significance to carry out basic research related to obesity.
  • lorcaserin The most common side effect of lorcaserin is headache, while the naltrexone/bupropion combination mainly has adverse reactions such as headache, dizziness, nausea and vomiting, diarrhea, constipation and insomnia.
  • the diet drug rimonabant which caused severe mental illness, and sibutramine, which increased the risk of cardiovascular disease, were discontinued in 2009 and 2010, respectively.
  • the object of the present invention is to provide acyltadine compounds with lipase inhibitory activity and a preparation method, as well as the application of the lipase inhibitors in weight control and obesity treatment.
  • n 2, 3 or 4;
  • n 2, 3 or 4;
  • Each R 1 , R 2 , R 3 , R 4 , R 5 is each independently selected from the following group: hydrogen, C 1 -C 4 alkyl or -OZ; wherein each Z is independently selected from the following group: hydrogen, C 3 -C 6 acyl; and, at least one of R 1 , R 2 , R 3 , R 4 , R 5 is -OZ;
  • R 1 ′, R 2 ′ , R 3 ′, R 4 ′, R 1 ′′, R 2 ′′, R 3 ′′, R 4 ′′, Ra are each independently selected from the following group: hydrogen, hydroxyl, C 1 -C 4 alkyl, halogen;
  • Each Y 2 and Y 3 are independently selected from the following group: -O-, -NH-;
  • R is not hydroxyl
  • each R 1 , R 2 , R 4 , R 1 ′, R 2 ′ , R 4 ′, R 1 ′′, R 2 ′′ , R 4 ′′, Ra are each independently selected from the following Group: hydrogen, C 1 -C 2 alkyl or hydroxy.
  • each R 2 is independently C 1 -C 2 alkyl.
  • each R 1 , R 2 , R 4 , R 1 ′, R 2 ′ , R 4 ′, R 1 ′′, R 2 ′′ , R 4 ′′, Ra are each independently selected from the following Group: hydrogen, C 1 -C 2 alkyl or hydroxy.
  • each R 2 is independently C 1 -C 2 alkyl.
  • the compound of formula (I) has the structure shown in formula (I-1) or formula (I-2),
  • R 3 is as defined above.
  • the compound of formula (I) is selected from:
  • a method for preparing the compound of formula (I), comprising: cultivating Streptomyces sp. HO1518, and isolating the compound of formula (I) from its culture product.
  • the culture product is a culture supernatant.
  • said isolating comprises purifying the culture product and isolating different compounds of formula (I) from different eluents.
  • the purification is preferably gradient elution.
  • the Streptomyces HO1518 Streptomyces sp. HO1518 is Streptomyces HO 1518 Streptomyces sp. HO1518 with a preservation number of CCTCC NO: M 2018176.
  • composition comprising:
  • the composition may contain other ingredients required as pharmaceuticals or foods.
  • proteins, lipids, carbohydrates, dietary fibers, vitamins, and the like may be contained.
  • the composition is selected from daily chemical products, foods, health products, and pharmaceutical compositions.
  • a kit comprising:
  • the compound of formula (I) described herein or its pharmaceutically or food-acceptable salt or ester, isomer, racemate, solvate, hydrate or precursor Use in the manufacture of a product for inhibiting lipase activity, controlling body weight, improving fat utilization, or preventing, alleviating or treating a disease or condition that would benefit from reduced fat absorption.
  • diseases or conditions that would benefit from reduced fat absorption include hyperlipidemia, obesity, or fat storage lipid metabolism disorders.
  • the lipase is selected from animal lipase, plant lipase, microbial lipase. In one or more embodiments, the lipase is animal lipase, preferably pancreatic lipase.
  • the product includes daily chemical products, food, health products, pharmaceutical compositions or kits.
  • a non-diagnostic, non-therapeutic method for inhibiting lipase activity comprising: making the compound of formula (I) described herein or its pharmaceutically or food-acceptable salt or ester, iso Constructs, racemates, solvates, hydrates or precursors are in contact with lipase-containing samples, thereby inhibiting the activity of lipase.
  • the method of inhibiting lipase activity is a non-diagnostic or therapeutic method.
  • the lipase is selected from animal lipase, plant lipase, microbial lipase. In one or more embodiments, the lipase is animal lipase, preferably pancreatic lipase.
  • a method of controlling body weight, improving fat utilization, or preventing, alleviating or treating a disease or condition benefiting from reduced fat absorption comprising: administering to a subject in need thereof an effective amount of The compound represented by formula (I) or its pharmaceutically or food acceptable salt or ester, isomer, racemate, solvate, hydrate or precursor.
  • the Streptomyces HO 1518 Streptomyces sp. HO1518 or its culture with the preservation number CCTCC NO: M 2018176 is provided for producing the compound represented by the formula (I) described herein.
  • a method for improving the inhibitory activity of amino oligosaccharides on lipase comprises: adding at least one acyl group to the amino oligosaccharide compound.
  • Figure 1A a diagram of the cleavage pattern of acyltadine compounds 2-5.
  • Fig. 2A a schematic diagram of the cleavage mode of acyltadine compounds 6-8.
  • Figure 4 The general structural formula of the alcatrazine family compounds in Streptomyces sp.HO1518.
  • A Aca-glu type
  • B glu-Aca-glu type
  • C incAca-glu type.
  • the present invention discloses a new class of acyl hepatidine compounds for the first time, and finds that the acyl hepatidine compounds have high-efficiency lipase inhibitory activity.
  • acyl hepatidine compound has a compound represented by formula (I),
  • n 2, 3 or 4;
  • n 2, 3 or 4;
  • Each R 1 , R 2 , R 3 , R 4 , R 5 is independently selected from the group consisting of hydrogen, C 1 -C 4 alkyl or -OZ;
  • each Z is independently selected from the following group: hydrogen, C 3 -C 6 acyl; and, at least one of R 1 , R 2 , R 3 , R 4 , R 5 is -OZ;
  • R 1 ′, R 2 ′ , R 3 ′, R 4 ′, R 1 ′′, R 2 ′′, R 3 ′′, R 4 ′′, Ra are each independently selected from the following group: hydrogen, hydroxyl, C 1 -C 4 alkyl, halogen;
  • Each of Y 2 and Y 3 is independently selected from the following group: -O-, -NH-.
  • the present invention also includes its pharmaceutically or food acceptable salts, isomers, racemates, solvates, hydrates or precursors of the compounds of the above formula (I), as long as they also have the same properties as those of the formula (I)
  • the compounds have the same or substantially the same function.
  • alkyl alone or in combination with other terms refers to a saturated aliphatic alkyl group, including straight or branched chain alkyl groups of 1-20 carbon atoms.
  • the alkyl group refers to a medium alkyl group containing 1-10 carbon atoms, such as methyl, ethyl, propyl, 2-isopropyl, n-butyl, isobutyl, tert-butyl, pentyl and Similar to alkyl.
  • alkyl group having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 2-isopropyl, n-butyl, isobutyl, t-butyl and the like.
  • Alkyl groups may be substituted or unsubstituted. When substituted, the number of substituents is 1 or more, preferably 1-3, more preferably 1 or 2, and the substituents are independently selected from halogen, hydroxyl, lower alkoxy and aryl.
  • alkenyl as used herein includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon double bond and 2-4 carbon atoms, preferably 2-3 carbon atoms.
  • alkynyl as used herein includes straight and branched chain hydrocarbon groups containing at least one carbon-carbon triple bond and 2-4 carbon atoms, preferably 2-3 carbon atoms.
  • halogen refers to F, Cl, Br, or I.
  • substituted refers to a compound having a substituent comprising at least one carbon atom, nitrogen atom, oxygen atom or sulfur atom with one or more hydrogen atoms. If a substituent is described as being “substituted,” it means that a non-hydrogen substituent occupies the position of a hydrogen on a carbon, nitrogen, oxygen, or sulfur.
  • the alkyl, alkenyl and alkynyl groups may be substituted; for example, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl.
  • a substituted group has a substituent at one or more appropriate positions, and when more than one position is substituted, the substituents at each substituted position may be the same or different.
  • the substituents of the substituted acyl include: hydroxyl, C1-C4 alkyl, C2-C4 Alkenyl, C2-C4alkynyl, halogen.
  • isomers as used herein includes: geometric isomers, enantiomers, diastereomers (such as cis-trans isomers, conformational isomers).
  • the compounds disclosed in the present invention or their salts may contain one or more asymmetric centers, so there will be enantiomers, diastereoisomers and other stereoisomeric forms that can be defined, and can be divided according to stereochemistry. is (R)- or (S)-, (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as racemic and optically pure forms.
  • Optically active (+) and (-), (R)- and (S)- or (D)- and (L)-isomers can be prepared by chiral synthons or chiral reagents, or by conventional techniques Such as the use of high performance liquid phase chiral column to separate the preparation.
  • the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise stated, it is meant that the compounds include both E and Z geometric isomers. Likewise, all tautomers are included.
  • the expression method of the ellipsis "" in the general formula is well known to those skilled in the art, which means that there is any, one or more omitted units.
  • the unit is structurally the same as the unit before "" or corresponding.
  • "food or pharmaceutically acceptable” ingredients are substances that are suitable for humans and/or animals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), that is, substances with a reasonable benefit/risk ratio.
  • the "food or pharmaceutically acceptable salts” mentioned herein include acid salts and basic salts.
  • “Pharmaceutically acceptable acid salt” refers to a salt that can maintain the biological activity and properties of the free base, and such salts will not have undesired biological activity or other changes.
  • Such salts may be formed from inorganic acids such as, but not limited to, hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, and the like.
  • Such salts may also be formed from organic acids such as, but not limited to, acetic acid, dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, Camphorsulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfonic acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, isethionic acid , formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxoglutaric acid, glycerophosphate , glycolic acid, hippuric acid, isobutyric acid, lactic
  • “Pharmaceutically acceptable basic salt” refers to a salt that can maintain the biological activity and properties of the free acid, and such salts will not have undesired biological activity or other changes. These salts are prepared by adding an inorganic or organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum and the like. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, primary, secondary, and tertiary ammonium salts, substituted amines include naturally substituted amines, cyclic amines, and basic ion exchange resins such as ammonia, isopropylamine, trimethylamine, di Ethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, tannol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, coffee Inine, procaine, halamine, choline, betaine, phenethylbenzylamine, N,N'-bisbenzylethylenediamine, ethylenediamine, glucosamine, methylglucosamine, theobromine, three Ethanolamine, tromethamine, purine, piperazine, piperidine, N-ethylpiperidine, polyamide
  • solvate refers to a polymer comprising one or more molecules of a compound disclosed herein and one or more solvent molecules.
  • the solvent may be water, in which case the solvate may be a hydrate.
  • the solvent may also be an organic solvent. Therefore, the compounds disclosed in this patent can exist as hydrates, including monohydrates, dihydrates, hemihydrates, sesquihydrates, trihydrates, tetrahydrates and similar structures, and can also be used as corresponding solvated products exist.
  • the compounds disclosed herein may be true solvates, while in other cases, the compounds disclosed herein may retain some water only, or a mixture of water and some solvent.
  • the "precursor of the compound” refers to that when taken in an appropriate way, the precursor of the compound undergoes metabolism or chemical reaction in the patient's body and converts into a compound of structural formula (I), or a compound of chemical structural formula (I). A salt or solution of a compound.
  • the term “comprising” means that various components can be used together in the mixture or composition of the present invention. Accordingly, the terms “consisting essentially of” and “consisting of” are included in the term “comprising”.
  • the compound of the present invention can be obtained by various methods well known in the art, using known raw materials, such as chemical synthesis or from organisms (such as microorganisms, especially is the method for extracting in Streptomyces), and these methods are all included in the present invention.
  • a method for preparing a compound represented by formula (I) of the present invention comprising: cultivating Streptomyces HO 1518 Streptomyces sp.HO1518, obtaining a culture product (preferably culturing supernatant), from which the compound of formula (I) is isolated. Afterwards, the culture product is purified, and different compounds of formula (I) are separated from different eluents.
  • the collection and purification of products are well known in the art, for example, resin adsorption and elution methods can be used.
  • the present invention also provides a composition
  • a composition comprising the compound of formula (I) described herein or its pharmaceutically or food-acceptable salt, isomer, racemate, solvate, hydrate or precursor, and pharmaceutically or food-acceptable excipients.
  • the composition can be a food, a health care product, or a pharmaceutical composition.
  • “food or pharmaceutically acceptable excipients” are used to combine the compound of formula (I) of the present invention or its pharmaceutically or food acceptable salts, isomers, racemates, solvates A pharmaceutically or food-acceptable carrier, solvent, suspending agent or excipient for delivering substances, hydrates or precursors to animals or humans.
  • Excipients can be liquid or solid and include but are not limited to: pH adjusters, surfactants, carbohydrates, adjuvants, antioxidants, chelating agents, ionic strength enhancers, preservatives, carriers, glidants, sweeteners , dye/colorant, flavor enhancer, wetting agent, dispersant, suspending agent, stabilizer, isotonic agent, solvent or emulsifier.
  • pharmaceutically acceptable excipients may include one or more inactive ingredients, including but not limited to: stabilizers, preservatives, additives, adjuvants, sprays, compressed air or other suitable gases, Or other suitable inactive ingredients used in combination with medicinal compounds. More specifically, suitable excipients may be excipients commonly used in the art for administration of plant extract components or nucleic acids.
  • the composition will contain a therapeutically effective amount of an agent described herein.
  • a therapeutically effective amount refers to a dose that can achieve treatment, prevention, alleviation and/or alleviation of a disease or condition in a subject.
  • the therapeutically effective dose can be determined according to factors such as the patient's age, sex, disease and its severity, and other physical conditions of the patient.
  • a therapeutically effective amount may be administered as a single dose, or may be administered in multiple doses in accordance with an effective treatment regimen.
  • a subject or a patient generally refers to a mammal, especially a human.
  • the composition contains, for example, 0.001-50% by weight, preferably 0.01-30%, more preferably 0.05-10% of the compound represented by formula (I) or its pharmaceutically or food-acceptable Salts, isomers, racemates, solvates, hydrates or precursors.
  • compositions described herein may be used in combination with other agents for weight management or therapeutic benefit from reduced fat absorption. Dosages of other agents to be administered can be determined by those skilled in the art.
  • the composition may also contain protein, lipid, carbohydrate, dietary fiber, vitamins and the like. Proteins such as milk protein (whole milk protein, sodium caseinate, calcium caseinate, etc.) and their hydrolysates, other animal proteins (egg protein, gelatin, etc.) things.
  • the composition of the present invention may contain protein as a main ingredient. The total protein content can be appropriately determined, but if the purpose is to ingest 1/3 of the daily required intake, it is preferably about 13 to 30 g/400 ml. Vitamins can also be added vitamins A, B1, B2, B6, B12, C, D, E, K2, niacin, pantothenic acid, folic acid, etc., which can be added alone or mixed.
  • the composition of the present invention may also contain dry yeast (eg brewer's yeast, baker's yeast, etc.).
  • the dosage form of the composition of the present invention can be varied, as long as the active ingredient can effectively reach the mammalian body, it can be made into a unit dosage form.
  • Dosage forms can be selected from, for example, gels, aerosols, tablets, capsules, powders, granules, syrups, solutions, suspensions, injections, powders, pills, controlled immediate releases, infusions, suspensions, and the like.
  • preferred compositions are solid compositions, especially tablets and solid-filled or liquid-filled capsules.
  • the compounds of the present invention or compositions thereof may also be stored in sterile devices suitable for injection or infusion.
  • the compounds of the present invention or compositions thereof may also be stored in suitable containers and placed in kits or kits.
  • the composition can also be a daily chemical product, such as shampoo, shower gel, cosmetics, washing powder and the like.
  • the present inventors found in the research that the compound represented by formula (I) has a high-efficiency inhibitory effect on lipase, so it is a good lipase inhibitor.
  • the compounds can control body weight, improve fat utilization, or prevent, alleviate or treat diseases or conditions that would benefit from reduced fat absorption.
  • disease or condition benefiting from reduced fat absorption generally refers to a disease, disorder or condition caused by accumulation of fat in an organ, tissue or cell due to excessive fat absorption by an organism, such as hyperlipidemia, obesity, obesity Type 2 diabetes and obesity-induced cancers (such as liver cancer, pancreatic cancer, colorectal cancer, ovarian cancer, etc.), cardiovascular diseases (coronary heart disease, hypertension, heart failure, etc.), etc.
  • Obesity is a common complication of type 2 diabetes. It will significantly increase insulin resistance and pancreatic ⁇ -cell load, reduce the body's ability to metabolize glucose, lead to further increase in blood sugar, and seriously affect the quality of life of diabetic patients.
  • the compound of the present invention inhibits the lipase activity in the gastrointestinal tract, prevents the degradation of fat in food, excretes the undecomposed lipase, reduces the intake of fat, thereby controlling or reducing the patient's weight and improving the patient's physical condition .
  • the present invention provides a method for inhibiting lipase activity, comprising: making the compound of formula (I) described herein or its pharmaceutically or food acceptable salt, isomer, external The racemate, solvate, hydrate or precursor is contacted with the lipase-containing sample, thereby inhibiting the activity of the lipase.
  • the present invention also provides a method for controlling body weight, improving fat utilization, or preventing, alleviating or treating diseases or conditions benefiting from reduced fat absorption, comprising: administering an effective amount of the formula (I) described herein to a subject in need thereof The indicated compound or its pharmaceutically or food acceptable salt, isomer, racemate, solvate, hydrate or precursor.
  • effective amount refers to the injection amount that can produce therapeutic functions for humans or animals and can be accepted by animals and humans.
  • concentration of the peptide can be 20 ng/mL Above, 50ng/mL, above 100ng/mL, etc.
  • the effective amount will vary with the mode of administration and the severity of the disease being treated. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as the exigencies of the therapeutic situation dictate.
  • the administration methods of the compounds of the present invention may include, but are not limited to, subcutaneous injection, transdermal injection, implantation, topical administration, intramuscular injection, sustained release administration, oral administration, and the like.
  • Those skilled in the art are aware of other agents needed to administer the drug to a subject under different modes of administration, doses, sites of administration, and the like.
  • the kit for implementing the above method comprises the compound represented by formula (I) described herein or its pharmaceutically or food-acceptable salt, isomer, racemate, solvate, hydrate or precursor, or
  • the compositions, and optionally other items required for their administration, and optionally instructions are, for example, measuring instruments, containers such as syringes, etc. required for using or administering the composition in various dosage forms.
  • the instructions are for directing the use or administration process.
  • the present invention also provides the compound of formula (I) described herein or its pharmaceutically or food acceptable salt, isomer, racemate, solvate, hydrate or precursor in the preparation of inhibiting lipase activity , use in a product for controlling body weight, improving fat utilization, or preventing, alleviating or treating a disease or condition that would benefit from reduced fat absorption.
  • the product can be daily chemical products, food, health products, pharmaceutical compositions or kits.
  • Aca acarviostatin; Ac, acetyl; Hac, hydroxyacetyl; Pr, propionyl; Hpr, hydroxypropionyl; Bu, butyryl; isoBu, isobutyryl; Hbu, hydroxybutyryl; Mbu, 2-methyl-butyryl; hexanoyl; Hhe, hydroxyhexanoyl; diHva, dihydroxyvaleryl.
  • Acarviostatins marked with “-” in Ref.column, are potential new compounds.
  • Embodiment 2 the fermentation culture of bacterial strain and the preparation of compound
  • Streptomyces strain HO 1518 Streptomyces sp.HO1518 was collected from marine sediments in the 50-100m deep sea area near Rizhao, Shandong, China in 2010, and its preservation number in the China Center for Type Culture Collection is CCTCC NO:M 2018176.
  • inorganic salts NaCl 24.4770, Na 2 SO 4 3.9170, KCl 0.664, SrCl 2 . 6H 2 O 0.0404, MgCl 2 . 6H 2 O 4.981, CaCl 2 0.9482, NaHCO 3 0.192, H 3 BO 3 0.026, NaF 0.004, dissolved in tap water and fixed to a certain volume to prepare artificial seawater; accurately weigh trace element metal salts (g/L): MnCl 2 0.389, NiSO 4 . 6H 2 O 0.056, LiCl 0.028, K 2 Cr 2 O 7 0.15, Na 2 EDTA 1.00, FeCl 3 .
  • PH medium Pulpamedia powder 1%, soluble starch 1%, glucose 1.2%, corn steep liquor dry powder 0.5%)
  • adjust the pH to 7.2 add 400mL PH medium (containing 400 ⁇ L trace element solution), sterilized by autoclaving at 121°C for 20 minutes, inoculated with HO 1518 seed solution after cooling, and cultured in a fermenter at 28°C and 200 rpm for 7 days, with a total of 35 L fermented.
  • the fermentation broth of strain HO1518 was centrifuged at high speed, and the supernatant was collected; the metabolites in the supernatant were adsorbed by macroporous resin XAD-16, and the crude extract of HO1518 was obtained.
  • the crude extract was subjected to C 18 reversed-phase silica gel column chromatography, and was eluted with different concentrations of methanol/water (5:95 ⁇ 100:0) gradient, and was divided into 6 fractions (Fr.1-Fr.6).
  • Fraction Fr.1 was subjected to ODS-C 18 reverse phase silica gel column chromatography, methanol/water gradient elution (5:95 ⁇ 100:0), and was divided into 6 subcomponents (Fr.1-1 ⁇ Fr.1- 6).
  • Subfraction Fr.1-1 was subjected to MCI column chromatography, and then purified by full preparative HPLC (MeCN/H 2 O, 6:94, 8mL/min), and the known compound 1 (alcaftadine II03, Aca II03, 10.0 mg, t R 10.5 min) and new compound 2 (alcaftadine II02, Aca II02, 1.6 mg, t R 9.6 min).
  • Subfraction Fr.1-3 was passed through the MCI column, and then purified by full preparative HPLC (MeCN/H 2 O, 10:90, 8mL/min) to obtain the known compound 11 ( ⁇ -hydroxybutyrylalcaftadine II03 , Hbu-Aca II03, 4.5 mg, t R 15.1 min).
  • Subcomponents Fr.1-4 were subdivided by MCI and ODS-C 18 column chromatography, and then purified by HPLC (MeCN/H 2 O, 10:90, 6mL/min) to obtain a new compound 6 (propionyl Alcaftadine II03, Pr-Aca II03, 13.2mg, t R 40.5min).
  • Subfractions Fr.1-5 were purified by reverse-phase silica gel and MCI column chromatography, followed by two HPLC preparative purifications (MeCN/H 2 O, 10:90, 6 mL/min; MeCN/H 2 O, 16:84 , 8mL/min); Obtain known compound 9 (alcastatine I03, Aca I03, 2.2mg, t R 6.0min) and 10 (butyryl alcastatine I03, Bu-Aca I03, 10.2mg, t R 14.3min).
  • Subfraction Fr.1-6 was purified by MCI column chromatography, and then purified by HPLC twice (MeCN/H 2 O, 10:90, 6mL/min; MeCN/H 2 O, 18:82, 8mL/min ); Obtain new compound 8 (2-methylbutyryl alcatadine II03, Mbu-Aca II03, 4.2 mg, t R 12.2min) and known compound 12 (isovaleryl alcatadine II03, isoVa-Aca II03, 6.2 mg, tR 12.8 min).
  • Fraction Fr.2 was subjected to gradient elution (MeOH/H 2 O, 5:95 ⁇ 100:0) using an MCI column, and was subdivided into 4 subcomponents.
  • Subfraction Fr.2-2 was purified by reverse-phase silica gel column chromatography, and then purified by HPLC twice (MeCN/H 2 O, 10:90, 6mL/min; MeCN/H 2 O, 16:84, 8mL /min), obtain new compound 7 (butyryl alcastatine II03, Bu-Aca II03, 5.9mg, t R 11.9min) and 4 (isobutyryl alcastatine II02, isoBu-Aca II02, 1.9mg, t R 10.4min).
  • Subfraction Fr.2-3 was purified twice by HPLC (MeCN/H 2 O, 10:90, 6mL/min; MeCN/H 2 O, 12:88, 8mL/min) to obtain the new compound 3 (Propionylalcatadine II02, Pr-Aca II02, 2.2mg, tR 17.0min).
  • Subfraction Fr.2-4 was purified by full preparative HPLC (MeCN/H 2 O, 6:94, 8mL/min) to obtain a new compound 5 (isovalerylalcastatine II02, isoVa-Aca II02, 2.0mg , t R 44.3min).
  • the full preparative column is SilGreen C 18 , 250 ⁇ 20mm; semi-preparative column is TSK-gel 100V C 18 , 250 ⁇ 10mm; the analytical detection column is Phenomenex/Luna C 18 (2) 100A, 4.6 ⁇ 250mm; UV detection wavelength is 210nm.
  • Embodiment 3 the chemical structure of the new compound of acyl hepatidine family
  • the seven new compounds obtained above are all colorless transparent solids, easily soluble in water, and the ultraviolet absorption is terminal absorption.
  • Alcaftadine II 02 (corresponding to compound 2) has a molecular formula of C 50 H 84 N 2 O 35 and a molecular weight of 1273.4927.
  • Propionatadine II 02 (corresponding to compound 3) has a molecular formula of C 53 H 88 N 2 O 36 and a molecular weight of 1329.5190.
  • Isobutyrate II 02 (corresponding to compound 4) has a molecular formula of C 54 H 90 N 2 O 36 and a molecular weight of 1343.5346.
  • Isovaleratadine II02 (corresponding to compound 5) has a molecular formula of C 55 H 92 N 2 O 36 and a molecular weight of 1357.5503.
  • Propionatadine II 03 (corresponding to compound 6) has a molecular formula of C 59 H 98 N 2 O 41 and a molecular weight of 1491.5718.
  • Butyrastatidine II 03 (corresponding to compound 7) has a molecular formula of C 60 H 100 N 2 O 41 and a molecular weight of 1505.5872.
  • 2-Methylbutyrazidine II 03 (corresponding to compound 8) has a molecular formula of C 61 H 102 N 2 O 41 and a molecular weight of 1519.6031.
  • the new compounds 1-4 of acyltadine belong to the skeleton type of alcaftadine family II 02, and they form common fragment ion peaks m/z 304(b2), 466(b3), 624(b4) in the fragmentation mode of positive ion mass spectrometry and 769(b5).
  • the fragment ion peaks and molecular ion peaks of compound 2-4 at m/z y5 and b3-b5 are 56, 70 and 84 degrees different from alcaftadine II 02, respectively unit of mass.
  • the above shows that the acyl substitution positions of acyltadine compounds 1-4 are all on the D ring.
  • the detailed fragmentation modes of the four compounds are shown in Figure 1A, and their HRESIMS/MS spectra are shown in Figures 1B-1E.
  • the new compound 6-8 of acyltadine belongs to the skeleton type II03 of the alcaftadine family, and in the fragmentation mode of positive ion mass spectrometry, it forms common fragment ion peaks m/z 304(b2), 466(b3), 624(b4) and 769(b5), which are the same as the mass spectrometry fragments of the precursor compound - alcaftadine II03; and the fragment ion peaks and molecular ion peaks at m/z y5-y8 and b6-b8 are the same as the mass spectrometry fragments of alcaftadine II03 The difference is 56, 70 and 84 mass units.
  • acyl substitution position of the acyltadine compound M-1b is also on the D ring.
  • the detailed fragmentation mode of compound M-1b is shown in Figure 2A, and its HRESIMS/MS spectra are shown in Figures 2B-2D.
  • acyltadine compounds obtained above belong to amino-oligosaccharide compounds. It is reported that such compounds have significant ⁇ -amylase inhibitory activity, but there is no literature report on their lipase inhibitory activity.
  • the inventor chose orlistat as a positive control, whose mechanism of action is to inhibit the activity of lipase in the gastrointestinal tract, prevent the hydrolysis of fat in food into free fatty acids and monoacylglycerols that can be absorbed by the human body, and directly discharge undecomposed fat In vitro, to prevent fat absorption from the source, so as to achieve the goal of easy weight loss.
  • Inhibition rate of pancreatic lipase activity/% [1-(A sample -A sample empty )/(A negative -A empty )] ⁇ 100

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de statine à base d'acyle ayant une activité inhibitrice de lipase, son procédé de préparation et son utilisation dans la régulation du poids corporel et le traitement de l'obésité.
PCT/CN2023/077498 2022-03-01 2023-02-21 Composé de statine à base d'acyle ayant une activité inhibitrice de lipase, son procédé de préparation et son utilisation WO2023165381A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202210195718.5 2022-03-01
CN202210195718.5A CN116731091A (zh) 2022-03-01 2022-03-01 具有脂肪酶抑制活性的酰基他定类化合物、其制备方法及应用

Publications (1)

Publication Number Publication Date
WO2023165381A1 true WO2023165381A1 (fr) 2023-09-07

Family

ID=87882894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/077498 WO2023165381A1 (fr) 2022-03-01 2023-02-21 Composé de statine à base d'acyle ayant une activité inhibitrice de lipase, son procédé de préparation et son utilisation

Country Status (2)

Country Link
CN (1) CN116731091A (fr)
WO (1) WO2023165381A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254256A (en) * 1977-12-28 1981-03-03 Toyo Jozo Company, Ltd. Amino sugar compound
CN1100756A (zh) * 1993-09-24 1995-03-29 华北制药集团新药研究开发中心 新的-α-淀粉酶抑制剂及其制备方法与应用
CN101998998A (zh) * 2008-04-11 2011-03-30 安斯泰来制药株式会社 氨基糖化合物及其生产方法
CN110386992A (zh) * 2018-04-16 2019-10-29 中国科学院上海生命科学研究院 具有α-糖苷酶抑制活性的酰基他定类化合物、其制备方法及应用
CN114073708A (zh) * 2020-08-19 2022-02-22 中国科学院分子植物科学卓越创新中心 具有糖苷酶抑制活性的酰基他定类化合物的应用
CN114075256A (zh) * 2020-08-19 2022-02-22 中国科学院分子植物科学卓越创新中心 具有脂肪酶抑制活性的酰基他定类化合物、其制备方法及应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254256A (en) * 1977-12-28 1981-03-03 Toyo Jozo Company, Ltd. Amino sugar compound
CN1100756A (zh) * 1993-09-24 1995-03-29 华北制药集团新药研究开发中心 新的-α-淀粉酶抑制剂及其制备方法与应用
CN101998998A (zh) * 2008-04-11 2011-03-30 安斯泰来制药株式会社 氨基糖化合物及其生产方法
CN110386992A (zh) * 2018-04-16 2019-10-29 中国科学院上海生命科学研究院 具有α-糖苷酶抑制活性的酰基他定类化合物、其制备方法及应用
CN114073708A (zh) * 2020-08-19 2022-02-22 中国科学院分子植物科学卓越创新中心 具有糖苷酶抑制活性的酰基他定类化合物的应用
CN114075256A (zh) * 2020-08-19 2022-02-22 中国科学院分子植物科学卓越创新中心 具有脂肪酶抑制活性的酰基他定类化合物、其制备方法及应用

Also Published As

Publication number Publication date
CN116731091A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
CA2304770C (fr) Utilisation de composes de saponine steroidien pour la prophylaxie ou le traitement de la senilite et nouveaux composes de saponine steroidien
CA2540108A1 (fr) Agent antitumoral comprenant un inhibiteur de l'histone desacetylase et un inhibiteur de la topoisomerase ii
AU2009251848A1 (en) Compositions and methods for immunotherapy
CN110386992B (zh) 具有α-糖苷酶抑制活性的酰基他定类化合物、其制备方法及应用
JPS6130521A (ja) 末梢神経障害の疼痛治療用ガングリオシド混合物
JP2012515801A (ja) 糖尿病及び肥満症を治療するためのプテロシン化合物の使用
EP4114408A1 (fr) Dérivés de nicotinamide mononucléotide et de bis-nicotinamide dinucléotide pour le traitement de l'arythmie
WO2011158904A1 (fr) Agent thérapeutique pour des maladies inflammatoires contenant de l'adénosine n1-oxyde en tant que principe actif
CN114075256B (zh) 具有脂肪酶抑制活性的酰基他定类化合物、其制备方法及应用
CN114073708A (zh) 具有糖苷酶抑制活性的酰基他定类化合物的应用
US7034058B2 (en) Anti-tumor pharmaceutical composition comprising N-vanillyl fatty acid amide
WO2023165381A1 (fr) Composé de statine à base d'acyle ayant une activité inhibitrice de lipase, son procédé de préparation et son utilisation
US6894034B1 (en) Sebum production inhibitors
JPS6112622A (ja) 造血幹細胞の分化増殖促進剤
JP3987909B2 (ja) 新規なデプシペプチド化合物
WO2023165382A1 (fr) Utilisation d'un composé d'acyltadine ayant une activité inhibitrice de glycosidase
CN111939259A (zh) Na/K-ATP酶抑制剂及其应用
JP4195107B2 (ja) ストレス蛋白質発現増強剤
EP0448029A2 (fr) Nouvelles utilisations pharmaceutiques des dérivés de la forskoline
JP5995235B2 (ja) シガテラを治療するためのロスマリン酸及びその誘導体の使用
US9468623B1 (en) Medical use of compound from Garcinia esculenta
BE1030299B1 (fr) Application de la 5'-méthylthioadénosine dans la préparation de médicaments ou de produits de santé anti-obésité
JPH11106335A (ja) 抗ヘリコバクター・ピロリ剤
KR100760999B1 (ko) Ｐｐａｒ감마를 활성화하는 찔레버섯 추출물 및 이로부터분리된 클로로페린 화합물
WO2021175335A1 (fr) Composé d'isopaucifloral f phosphate et son utilisation pharmaceutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23762781

Country of ref document: EP

Kind code of ref document: A1